Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGIOS PHARMACEUTICALS, INC. Director's Dealing 2020

Jun 1, 2020

31580_dirs_2020-06-01_3e7afcbb-9fc4-4f8d-8469-afc9df872ced.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2020-05-28

Reporting Person: Scadden David (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2020-05-29 Common stock M 1878 Acquired 3849 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-05-28 Stock options (right to buy) $53.35 A 8096 Acquired 2030-05-28 Common stock (8096.0) Direct
2020-05-28 Restricted stock units $ A 1686 Acquired Common stock (1686.0) Direct
2020-05-29 Restricted stock units $ M 1878 Disposed Common stock (1878.0) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021.

F3: The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.

F4: The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested.